1049P Clinical Outcomes in Patients (pts) with Tumor PD-L1 < 1% with First-Line (1L) Nivolumab (NIVO) + Ipilimumab (IPI) + 2 Cycles of Chemotherapy (chemo) Vs Chemo Alone for Metastatic NSCLC (mnsclc): Results from CheckMate 9LA

T. John,T-E. Ciuleanu,M. Cobo Dols,M. Schenker,B. Zurawski,J. Menezes,E. A. Richardet,J. Bennouna,Y. Cheng,E. Felip,O. J. Juan Vidal,A. Alexandru,L. Paz-Ares,S. Lu,M. Reck,N. Hu,X. Zhang,D. J. Grootendorst,L. Eccles,D. P. Carbone

DOI: https://doi.org/10.1016/j.annonc.2022.07.1175

IF: 51.769

2022-01-01

Annals of Oncology

Abstract:First-line immunotherapy-based regimens have limited efficacy in pts with mNSCLC and tumor PD-L1 < 1%. A high unmet medical need remains in mNSCLC, particularly in pts with squamous (SQ) mNSCLC or baseline brain metastasis (BM). In CheckMate 9LA (NCT03215706), 1L NIVO + IPI + 2 cycles of chemo showed long-term, durable benefit vs chemo in pts with mNSCLC, regardless of tumor PD-L1 status. Here we report an exploratory analysis of efficacy and safety in pts with tumor PD-L1 < 1% by histology or the presence of BM. Adults with stage IV/recurrent NSCLC, ECOG PS ≤ 1, and no sensitizing EGFR/ALK alterations were randomized 1:1 to 1L NIVO (360 mg Q3W) + IPI (1 mg/kg Q6W) + chemo (Q3W, 2 cycles) or chemo alone (Q3W, 4 cycles). Overall survival (OS), progression-free survival, objective response rate, duration of response, and safety were assessed in pts with tumor PD-L1 < 1% by histology (non-SQ [NSQ] or SQ) or by the presence of baseline BM (by blinded independent central review). Baseline characteristics in pts with tumor PD-L1 < 1% were generally similar to the ITT population. With a minimum follow-up of 36.1 mo (database lock: Feb 15, 2022), survival and efficacy outcomes were improved with NIVO + IPI + chemo vs chemo alone in pts with PD-L1 < 1% and NSQ or SQ histology (Table). Similarly, OS was improved with NIVO + IPI + chemo vs chemo in pts with (n = 17 vs 15) or without (n = 118 vs 114) BM; median OS was 20.6 vs 6.9 mo (HR 0.28, 95% CI 0.13–0.61) and 16.4 vs 11.2 mo (HR 0.72, 95% CI 0.54–0.96), respectively. No new safety signals were observed.Table1049P Efficacy outcomes in pts with tumor PD-L1 < 1% by histologyNSQSQNIVO + IPI + chemo n = 99Chemo n = 93NIVO + IPI + chemo n = 36Chemo n = 36Median OS, mo (95% CI)18.6 (13.2–22.7)12.4 (7.7–15.2)15.3 (9.9–22.2)8.0 (6.6–11.5)OS HR (95% CI) vs chemo0.74 (0.54–1.02)0.50 (0.30–0.83)3-y OS rate, %25192563-y PFS rate, %162194ORR, n (%)26 (26)14 (15)17 (47)12 (33)Median DOR, mo (95% CI)17.5 (4.4–38.9)7.1(3.0–9.7)18.7 (6.0–NA)2.8(2.6–4.6)CI, confidence interval; DOR, duration of response; HR, hazard ratio; NA, not available; ORR, objective response rate; PFS, progression-free survival. Open table in a new tab CI, confidence interval; DOR, duration of response; HR, hazard ratio; NA, not available; ORR, objective response rate; PFS, progression-free survival. First-line NIVO + IPI + chemo showed long-term, durable clinical benefit in pts with mNSCLC and tumor PD-L1 < 1% regardless of histology or the presence of baseline BM. These exploratory results were consistent with previous reports from all randomized pts and further support NIVO + IPI + chemo as a 1L treatment option for pts with mNSCLC.